Screener
Altimmune ALT CapEx
CapEx at other companies
Other financials
Where this comes from
Reported directly by Altimmune in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: Altimmune’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 4:13 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001326190-26-000040
| Line item | Three Months Ended / March 31, 2026 | Three Months Ended / March 31, 2025 |
|---|---|---|
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||
| Proceeds from sales and maturities of short-term investments | 39,622 | 38,040 |
| Purchases of short-term investments | (43,291) | (43,141) |
| Purchases of property and equipment | (21) | — |
| Net cash used in investing activities | (3,690) | (5,101) |
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||
| Payments of deferred offering costs | (89) | (125) |
| Proceeds from issuance of common stock in at-the-market offerings, net | 8,742 | 34,748 |
Item 1. Financial Statements
FAQ
- What is Altimmune's capex?
- Altimmune (ALT) reported capex of $21K in Q1 2026.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about Altimmune's capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude